New anti-cancer drug, Tucatinib, reduces risk of death in metastatic HER2+ breast cancer
Background There is significant unmet medical need following treatment with Herceptin, Perjeta and Kadcyla in patients with metastatic HER2-positive breast cancer. In the HER2CLIMB trial, the addition of tucatinib to…